{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:03:48Z","timestamp":1790525028660,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012997","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000}}],"reference-count":70,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012997.pub2","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:56:40Z","timestamp":1625446600000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome"],"prefix":"10.1002","volume":"2021","author":[{"given":"Aamer","family":"Imdad","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition; SUNY Upstate Medical University; Syracuse NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel P","family":"Mackoff","sequence":"additional","affiliation":[{"name":"College of Medicine; SUNY Upstate Medical University; Syracuse NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Urciuoli","sequence":"additional","affiliation":[{"name":"College of Medicine; SUNY Upstate Medical University; Syracuse NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamkeenat","family":"Syed","sequence":"additional","affiliation":[{"name":"Meharry Medical College; Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E","family":"Tanner-Smith","sequence":"additional","affiliation":[{"name":"Counseling Psychology and Human Services; University of Oregon; Eugene Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Nephrology; SUNY Upstate Medical University; Syracuse NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar G","family":"Gomez-Duarte","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics; University at Buffalo, State University of New York; Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD012997.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00005176-199910000-00015","article-title":"Bovine colostrum ameliorates diarrhea in infection with diarrheagenic Escherichia coli, shiga toxin-producing E. Coli, and E. coli expressing intimin and hemolysin","volume":"29","author":"Huppertz","year":"1999","journal-title":"Journal of Pediatric Gastroenterology & Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00343-09","article-title":"Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli","volume":"54","author":"Lopez","year":"2010","journal-title":"Antimicrobial Agents & Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD012997.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0022-3476(05)81209-0","article-title":"Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis","volume":"121","author":"Proulx","year":"1992","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0004|cit4","first-page":"C111","article-title":"Design and methodology of a randomized trial of Synsorb PK for the prevention of hemolytic uremic syndrome (HUS) [abstract no: P225]","volume":"9","author":"Rowe","year":"1995","journal-title":"Pediatric Nephrology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012997.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1203\/00006450-199704001-01703","article-title":"A phase II randomized controlled trial of Synsorb PK for the prevention of hemolytic uremic syndrome in children with verotoxin-producing E. coli (VTEC) gastroenteritis [abstract no: 1684]","volume":"41","author":"Rowe","year":"1997","journal-title":"Pediatric Research"},{"issue":"8","key":"10.1002\/14651858.CD012997.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00467-011-1867-0","article-title":"Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy","volume":"26","author":"Caletti","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08860220600778902","article-title":"Urinary podocyte mRNA excretion in children with D+HUS: a potential marker of long-term outcome","volume":"28","author":"De Petris","year":"2006","journal-title":"Renal Failure"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/JCM.36.6.1608-1611.1998","article-title":"Sensitivities and specificities of premier E. coli O157 and premier EHEC enzyme immunoassays for diagnosis of infection with verotxin (Shiga-like toxin)-producing Escherichia coli. The SYNSORB Pk Study investigators","volume":"36","author":"Mackenzie","year":"1998","journal-title":"Journal of Clinical Microbiology"},{"issue":"3","key":"10.1002\/14651858.CD012997.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1681\/ASN.V133699","article-title":"Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome","volume":"13","author":"Ray","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD012997.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"September, Prog","key":"10.1002\/14651858.CD012997.pub2-BIB0011|cit11","first-page":"6A","article-title":"Failure of an oral shiga toxin binding agent to ameliorate diarrheal-related hemolytic uremic syndrome: results of a randomized clinical trial [abstract no: F-FC027]","volume":"13","author":"Trachtman","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD012997.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00467-006-0146-y","article-title":"Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury","volume":"21","author":"Trachtman","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012997.pub2-BIB0013|cit13","first-page":"316A","article-title":"Urinary excretion of neutrophil gelatinase-associated lipocalcin (NGAL) in diarrhea-associated hemolytic uremic syndrome (D+HUS) [abstract no: TH-PO901]","volume":"16","author":"Trachtman","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD012997.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","article-title":"Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial","volume":"290","author":"Trachtman","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0015|cit15","unstructured":"Garnier A Eculizumab in shiga-toxin related hemolytic and uremic syndrome pediatric patients - ECULISHU (ECULISHU) www.clinicaltrials.gov\/ct2\/show\/NCT02205541"},{"issue":"5","key":"10.1002\/14651858.CD012997.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00467-008-1087-4","article-title":"Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial","volume":"24","author":"Pape","year":"2009","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD012997.pub2-BIB0017|cit17","first-page":"1598","article-title":"Early erythropoietin for preventing red blood cell transfusion in childhood hemolytic uremic syndrome [abstract no: P006]","volume":"23","author":"Pape","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0018|cit18","first-page":"C30","article-title":"The use of synsorb PK for preventing hemolytic uremic syndrome (HUS) [abstract]","volume":"9","author":"McLaine","year":"1995","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0019|cit19","unstructured":"Freedman S Shiga toxin producing Escherichia coli (STEC) volume expansion www.clinicaltrials.gov\/show\/NCT03275792"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0020|cit20","unstructured":"Sanguineti S Phase 2\/3 study to evaluate PK, safety and efficacy of INM004 in STEC positive pediatric patients for prevention of HUS www.clinicaltrials.gov\/show\/NCT04132375"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012997.pub2-BIB0021|cit21","first-page":"18","article-title":"SHIGATEC: a phase II study evaluating shigamabs in STEC-infected children [abstract]","volume":"59","author":"Bitzan","year":"2012","journal-title":"Zoonoses & Public Health"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0022|cit22","unstructured":"Lopez EL Cleary T Reymond D SHIGATEC Trial: a phase II study assessing monoclonal antibodies against shiga toxin 1 and 2 in shiga toxin-producing E. coli-infected children [abstract no: 609] Infectious Diseases Society of America Annual Meeting; 2011 Oct 20-23; Boston, USA 2011"},{"issue":"9","key":"10.1002\/14651858.CD012997.pub2-BIB0023|cit23","first-page":"1595","article-title":"Shigatec: a phase II study assessing monoclonal antibodies against shiga toxin 1 and 2 in Shiga toxin-producing E. coli-infected children [abstract no: PS1-THU-069]","volume":"26","author":"Taylor","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e20152153","DOI":"10.1542\/peds.2015-2153","article-title":"Early volume expansion and outcomes of hemolytic uremic syndrome","volume":"137","author":"Ardissino","year":"2016","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/infdis\/164.6.1160","article-title":"Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences","volume":"164","author":"Armstrong","year":"1991","journal-title":"Journal of Infectious Diseases"},{"issue":"17","key":"10.1002\/14651858.CD012997.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1994.03520170059036","article-title":"A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience","volume":"272","author":"Bell","year":"1994","journal-title":"JAMA"},{"issue":"112","key":"10.1002\/14651858.CD012997.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/ki.2008.624","article-title":"Treatment options for HUS secondary to Escherichia coli O157:H7","author":"Bitzan","year":"2009","journal-title":"Kidney International - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00005176-199207000-00010","article-title":"Field trial of an infant formula containing anti-rotavirus and anti-Escherichia coli milk antibodies from hyperimmunized cows","volume":"15","author":"Brunser","year":"1992","journal-title":"Journal of Pediatric Gastroenterology & Nutrition"},{"issue":"12","key":"10.1002\/14651858.CD012997.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1128\/JCM.02056-13","article-title":"Clinical evaluation of a real-time PCR assay for identification of Salmonella, Shigella, Campylobacter (Campylobacter jejuni and C. coli), and shiga toxin-producing Escherichia coli isolates in stool specimens","volume":"51","author":"Buchan","year":"2013","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0030|cit30","unstructured":"Centers for Disease Control and Prevention Hemolytic uremic syndrome, post-diarrheal (HUS). 1996 case definition wwwn.cdc.gov\/nndss\/conditions\/hemolytic-uremic-syndrome-post-diarrheal\/case-definition\/1996\/"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0031|cit31","unstructured":"Centers for Disease Control and Prevention E. coli (Escherichia coli). Resources for clinicians and laboratories. Guidance to healthcare providers and clinical laboratories www.cdc.gov\/ecoli\/clinicians.html"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0032|cit32","unstructured":"Centers for Disease Control and Prevention FoodNet:FAST: HUS wwwn.cdc.gov\/FoodNetFast\/HUS"},{"issue":"11","key":"10.1002\/14651858.CD012997.pub2-BIB0033|cit33","first-page":"365","article-title":"Hemolytic-uremic syndrome [Erratum in: Pediatr Rev 2002 Jan;23(1): 1 p]","volume":"22","author":"Boineau","year":"2001","journal-title":"Pediatrics in Review"},{"issue":"5","key":"10.1002\/14651858.CD012997.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1128\/AAC.49.5.1808-1812.2005","article-title":"Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers","volume":"49","author":"Dowling","year":"2005","journal-title":"Antimicrobial Agents & Chemotherapy"},{"issue":"10095","key":"10.1002\/14651858.CD012997.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0036|cit36","unstructured":"What is a serious adverse event? www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"issue":"10","key":"10.1002\/14651858.CD012997.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/cid\/ciw099","article-title":"Shiga toxin-producing Escherichia coli Infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis","volume":"62","author":"Freedman","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD012997.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","article-title":"Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression","volume":"290","author":"Garg","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD012997.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1532-5415.2011.03269.x","article-title":"Postdiarrheal hemolytic uremic syndrome in persons aged 65 and older in foodnet sites, 2000-2006","volume":"59","author":"Gould","year":"2011","journal-title":"Journal of the American Geriatrics Society"},{"issue":"7650","key":"10.1002\/14651858.CD012997.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012997.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2016.2952","article-title":"Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli: a systematic review and meta-analysis","volume":"171","author":"Grisaru","year":"2017","journal-title":"JAMA Pediatrics"},{"issue":"7414","key":"10.1002\/14651858.CD012997.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0044|cit44","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"21","key":"10.1002\/14651858.CD012997.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012997.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.hoc.2015.01.007","article-title":"Shiga toxin associated hemolytic uremic syndrome","volume":"29","author":"Keir","year":"2015","journal-title":"Hematology - Oncology Clinics of North America"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00343-09","article-title":"Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli","volume":"54","author":"Lopez","year":"2010","journal-title":"Antimicrobial Agents & Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/fpd.2013.1704","article-title":"Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis","volume":"11","author":"Majowicz","year":"2014","journal-title":"Foodborne Pathogens & Disease"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"24913","DOI":"10.1038\/srep24913","article-title":"Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against hemolytic uremic syndrome (HUS)","volume":"6","author":"Mejias","year":"2016","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1002\/14651858.CD012997.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele","year":"2014","journal-title":"Seminars in Immunopathology"},{"issue":"5","key":"10.1002\/14651858.CD012997.pub2-BIB0051|cit51","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EHEC-0013-2013","article-title":"New therapeutic developments against Shiga toxin-producing Escherichia coli","volume":"2","author":"Melton-Celsa","year":"2014","journal-title":"Microbiology Spectrum"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003595.pub2","article-title":"Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura","author":"Michael","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012997.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00496847","article-title":"Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins","volume":"132","author":"Mietens","year":"1979","journal-title":"European Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD012997.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jpeds.2014.12.064","article-title":"Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death","volume":"166","author":"Mody","year":"2015","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD012997.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.2012.264","article-title":"Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4","volume":"307","author":"Nitschke","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD012997.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ajg.2016.126","article-title":"ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults","volume":"111","author":"Riddle","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012997.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM198303243081203","article-title":"Hemorrhagic colitis associated with a rare Escherichia coli serotype","volume":"308","author":"Riley","year":"1983","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012997.pub2-BIB0058|cit58","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EHEC-0002-2013","article-title":"Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases","volume":"2","author":"Rivas","year":"2014","journal-title":"Microbiology Spectrum"},{"issue":"5","key":"10.1002\/14651858.CD012997.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-3476(98)70303-8","article-title":"Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. Investigators of the Canadian Pediatric Kidney Disease Research Center","volume":"132","author":"Rowe","year":"1998","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0060|cit60","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0061|cit61","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1542\/peds.94.1.35","article-title":"A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah","volume":"94","author":"Siegler","year":"1994","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0063|cit63","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00099-15","article-title":"New monoclonal antibodies against a novel subtype of Shiga toxin 1 produced by Enterobacter cloacae and their use in analysis of human serum","volume":"1","author":"Skinner","year":"2016","journal-title":"Msphere"},{"issue":"6","key":"10.1002\/14651858.CD012997.pub2-BIB0064|cit64","first-page":"441","article-title":"Hemolytic uremic syndrome in children","volume":"68","author":"Talarico","year":"2016","journal-title":"Minerva Pediatrica"},{"key":"10.1002\/14651858.CD012997.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1186\/1471-2458-13-799","article-title":"Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review","volume":"13","author":"Thomas","year":"2013","journal-title":"BMC Public Health"},{"issue":"10","key":"10.1002\/14651858.CD012997.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","article-title":"Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial","volume":"290","author":"Trachtman","year":"2003","journal-title":"JAMA"},{"issue":"26","key":"10.1002\/14651858.CD012997.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","article-title":"The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections","volume":"342","author":"Wong","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012997.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/cis299","article-title":"Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis","volume":"55","author":"Wong","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD012997.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00467-020-04560-0","article-title":"Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome","volume":"35","author":"Ylinen","year":"2020","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD012997.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012997","article-title":"Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome","author":"Imdad","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd012997.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T07:24:26Z","timestamp":1667978666000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012997.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":70,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012997.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]}}}